Opportunity Information: Apply for PAR 18 752
The National Cancer Institute (NCI) administrative supplement opportunity PAR-18-752 was created under the Cancer Moonshot initiative to speed up progress in cancer research, specifically around why cancers become resistant to treatment or, in some cases, unusually sensitive to certain drugs. It was developed in response to guidance from the Cancer Moonshot Blue Ribbon Panel, which identified major research areas where targeted investment and coordination could quickly move the field forward. Rather than funding entirely new standalone projects, this program provides add-on (supplemental) funds to strengthen and extend existing NCI-funded grants and cooperative agreements through new collaborations connected to a Moonshot-supported network.
At the center of the program is the Drug Resistance and Sensitivity Network (DRSN), a group of centers of excellence funded through U54 cooperative agreements. These DRSN centers are set up to use advanced experimental systems, analytical approaches, and disease models to better understand mechanisms of resistance and exceptional sensitivity to anticancer agents. The network also has a practical, translational role: it is intended to help address drug resistance issues that arise during the development of NCI investigational new drug (IND) agents, including agents being developed jointly with pharmaceutical partners and evaluated in NCI-sponsored early-phase clinical trials. In other words, the DRSN is meant to be both discovery-oriented (mechanisms and biology) and pipeline-oriented (supporting therapeutic development decisions).
This supplement FOA is aimed at investigators who already hold an active NCI grant or cooperative agreement and want to add a new, interdisciplinary collaboration with investigators at a DRSN U54 center. A key feature is that these collaborations are intended to connect non-U54 investigators (researchers not funded through the DRSN U54 awards) with DRSN-funded teams, so that existing NCI-funded projects can plug into the DRSN expertise, platforms, and model systems. The work supported must stay within the scientific scope of the parent award (or awards), meaning the supplement is meant to expand or accelerate the funded project rather than redirect it into an unrelated area.
Scientifically, the goal is to generate improved preclinical evaluations and stronger evidence around new findings in cancer drug resistance. The expectation is that supplement-supported studies will sharpen the understanding of resistance or sensitivity in ways that can inform the next steps in therapy development. While the ultimate vision is to enable findings that could later be tested in NCI-sponsored clinical trials, this specific opportunity is labeled “Clinical Trial Not Allowed,” so the funded supplement activities themselves must remain preclinical and not include conducting a clinical trial.
From an administrative standpoint, the award is issued as a grant supplement under a discretionary funding program administered by the U.S. Department of Health and Human Services through the National Institutes of Health. The opportunity listed an award ceiling of $250,000 and anticipated making about two awards. It is associated with CFDA numbers 93.394 and 93.395. The original posting date was April 11, 2018, with an original closing date of June 30, 2018, reflecting that it was a time-bound call for administrative supplements rather than an ongoing multi-year standalone mechanism.
Eligibility is broad and spans many organization types that can hold NIH/NCI awards, including state, county, and city governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses); small businesses; and other entities as described in the NIH eligibility language. In practical terms, the applicant must already have an eligible, active NCI-funded parent award to which the supplement would be attached, and the proposed collaboration must be justified as a scoped extension of that existing project.
Overall, PAR-18-752 is best understood as a Moonshot-driven bridge between the broader NCI-funded research community and the specialized DRSN U54 centers. It uses administrative supplements to rapidly catalyze collaborative, preclinical work on drug resistance and exceptional sensitivity, with the longer-term intent of improving the quality and readiness of discoveries that may eventually support NCI-sponsored clinical testing, without funding clinical trials directly under this supplement mechanism.Apply for PAR 18 752
- The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.395.
- This funding opportunity was created on Apr 11, 2018.
- Applicants must submit their applications by Jun 30, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NCI Administrative Supplement PAR-18-752 (Cancer Moonshot / DRSN)
1) What is PAR-18-752?
PAR-18-752 is a National Cancer Institute (NCI) administrative supplement opportunity created under the Cancer Moonshot initiative. It provides add-on funding to strengthen and extend existing, active NCI-funded grants and cooperative agreements through new collaborations focused on cancer drug resistance and exceptional drug sensitivity.
2) What is the main purpose of this supplement opportunity?
The main purpose is to speed progress in cancer research by supporting preclinical collaborative studies that help explain why cancers become resistant to treatment, or why some cancers show unusually strong sensitivity to certain anticancer drugs. The intent is to generate improved preclinical evaluations and stronger evidence that can inform next steps in therapy development.
3) How does this differ from applying for a brand-new research grant?
This is not a standalone mechanism for entirely new projects. It is an administrative supplement, meaning it adds funds to an already active NCI award. The supplement work must remain within the scientific scope of the parent award and is intended to expand, accelerate, or strengthen the existing funded research rather than redirect it into an unrelated area.
4) What is the Drug Resistance and Sensitivity Network (DRSN)?
The DRSN is a network of centers of excellence funded through U54 cooperative agreements. These centers use advanced experimental systems, analytical approaches, and disease models to understand mechanisms of resistance and exceptional sensitivity to anticancer agents. The network is also designed to be translational, supporting practical decisions in therapeutic development where resistance problems arise.
5) What role do the DRSN U54 centers play in this program?
The DRSN U54 centers are the collaboration hubs for this supplement. The opportunity is designed to connect investigators who are not part of the DRSN U54 awards with DRSN-funded teams, allowing existing NCI-funded projects to plug into the DRSN expertise, platforms, and model systems.
6) Who is this supplement intended for?
This supplement is intended for investigators who already hold an active NCI grant or cooperative agreement and who want to add a new interdisciplinary collaboration with investigators at a DRSN U54 center. In practical terms, you must have an eligible, active NCI-funded parent award that can receive the supplement.
7) Do applicants need to already be part of a DRSN U54 award to apply?
No. A key feature of the opportunity is to create new collaborations that connect non-U54 investigators with DRSN U54 centers. The supplement is meant to bring the broader NCI-funded research community into collaborative work with the DRSN centers.
8) What kinds of research does the supplement support?
The supplement supports preclinical collaborative studies that improve understanding of cancer drug resistance or exceptional sensitivity and strengthen preclinical evidence around new findings. The expectation is that the work will sharpen insights that can guide subsequent therapy development steps.
9) Is the work required to be within the scope of the parent award?
Yes. The supplement-supported activities must remain within the scientific scope of the parent grant or cooperative agreement. The supplement is intended to extend or enhance what is already funded, not to create a new, unrelated research direction.
10) Are clinical trials allowed under this opportunity?
No. This opportunity is labeled "Clinical Trial Not Allowed." The supplement activities must remain preclinical and cannot include conducting a clinical trial under this supplement mechanism.
11) Does the program have a connection to NCI-sponsored clinical trials anyway?
Yes, in a longer-term and indirect way. While the supplement itself cannot fund a clinical trial, the overall vision is to improve the quality and readiness of discoveries that could later support testing in NCI-sponsored clinical trials.
12) How does the DRSN connect to NCI investigational new drug (IND) development?
The DRSN is intended to help address drug resistance issues that arise during the development of NCI investigational new drug (IND) agents. This includes agents being developed with pharmaceutical partners and evaluated in NCI-sponsored early-phase clinical trials, even though this supplement funds only preclinical work.
13) What agency administers this funding?
The award is administered by the U.S. Department of Health and Human Services through the National Institutes of Health (NIH), with the National Cancer Institute (NCI) as the relevant institute.
14) What is the maximum award amount mentioned for this opportunity?
The opportunity listed an award ceiling of $250,000.
15) How many awards were anticipated?
The opportunity anticipated making about two awards.
16) What are the CFDA numbers associated with this opportunity?
The opportunity is associated with CFDA numbers 93.394 and 93.395.
17) When was PAR-18-752 originally posted and when did it close?
The original posting date was April 11, 2018, and the original closing date was June 30, 2018. The dates reflect that this was a time-bound call for administrative supplements rather than an ongoing multi-year standalone mechanism.
18) What types of organizations were eligible (in general terms)?
Eligibility was broad and included many organization types that can hold NIH/NCI awards, such as state, county, and city governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses); small businesses; and other entities as described in NIH eligibility language.
19) What is the practical eligibility requirement beyond organization type?
Beyond being an eligible organization type, the applicant must already have an eligible, active NCI-funded parent award to which the supplement would be attached, and the proposed DRSN collaboration must be justified as a scoped extension of that existing project.
20) How should someone think about PAR-18-752 in one sentence?
PAR-18-752 is a Cancer Moonshot-driven administrative supplement designed to rapidly catalyze collaborative, preclinical work on drug resistance and exceptional sensitivity by linking existing NCI-funded projects with the specialized capabilities of the DRSN U54 centers, without funding clinical trials.
Browse more opportunities from the same category: Education, Health
Next opportunity: Online Cultural Resources of Glacier National Park
Previous opportunity: Rocky Mountain National Park Trails Work 2018
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 752
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 752) also looked into and applied for these:
| Funding Opportunity |
|---|
| NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required) Apply for RFA CA 18 016 Funding Number: RFA CA 18 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UG1 Clinical Trial Required) Apply for RFA CA 18 017 Funding Number: RFA CA 18 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) Apply for RFA CA 18 015 Funding Number: RFA CA 18 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Required) Apply for RFA CA 19 017 Funding Number: RFA CA 19 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional) Apply for PAS 18 915 Funding Number: PAS 18 915 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not Allowed) Apply for RFA CA 19 016 Funding Number: RFA CA 19 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,600,000 |
| Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program (Admin Suppl - Clinical Trial Not Allowed) Apply for PA 18 934 Funding Number: PA 18 934 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional) Apply for RFA DA 19 008 Funding Number: RFA DA 19 008 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed) Apply for PAR 19 032 Funding Number: PAR 19 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl Clinical Trial Not Allowed) Apply for PA 19 035 Funding Number: PA 19 035 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) Apply for RFA CA 19 013 Funding Number: RFA CA 19 013 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $900,000 |
| HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional) Apply for RFA DA 19 024 Funding Number: RFA DA 19 024 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed) Apply for RFA DA 19 023 Funding Number: RFA DA 19 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) Apply for RFA CA 19 029 Funding Number: RFA CA 19 029 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) Apply for RFA CA 19 030 Funding Number: RFA CA 19 030 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) Apply for RFA CA 19 022 Funding Number: RFA CA 19 022 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) Apply for RFA CA 19 021 Funding Number: RFA CA 19 021 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) Apply for RFA CA 19 020 Funding Number: RFA CA 19 020 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) Apply for RFA CA 19 019 Funding Number: RFA CA 19 019 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 19 027 Funding Number: RFA CA 19 027 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 752", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.